U.S. FDA approves Eisai’s DayVigo (Lemborexant) for the treatment of insomnia in adult patients! The FDA approved the new drug application for its in-house discovered and developed orexin receptor antagonist DayVigo (lemborexant). DayVigo was approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. In the United States, DayVigo will be commercially available in 5 mg and 10 mg tablets following scheduling by the U.S. Drug Enforcement Administration (DEA), which is expected to occur within 90 days.
To learn more about the outcomes of this study and the new approved medication click here.
